Medical Marijuana Market to Witness Stunning Growth to Generate Massive Revenue during Forecast 2021 - 2027
iCrowd Newswire
The
Global Medical Marijuana Market is studied in detail in the new report on Qualiket Research. The new report studies the Medical Marijuana market by profiling its major driving factors and restraining factors, compiling a comprehensive database on the market s historical growth trajectory and present conditions, and by using easy formulation of calculations and estimations through the use of industry-leading analytical tools and methods.
Marijuana is a chemical plant which contains cannabis as a medical property. It is used as raw material by various pharmaceutical companies to manufacture drugs for different therapeutic applications. Marijuana extract is used to treat various diseases including Alzheimer s disease, Migraine, Arthritis, Chronic Pain, and Others.
TORONTO, June 03, 2021 Field Trip Health Ltd. , a leader in the development and delivery of psychedelic therapies, is pleased to announce that its common shares will commence trading on.
VIVO Cannabis Inc.: VIVO Cannabis Launches Premium Topical CBD Cream Infused with Terpenes: Unique Formulation Designed for Medical Users
VIVO Cannabis Inc. (
VIVO or the
Company ), a leading provider of premium cannabis products and services and holder of licenses under the Cannabis Act through its wholly-owned subsidiaries, Canna Farms Limited ( Canna Farms ) and ABcann Medicinals Inc. ( ABcann ), today announced the launch of Beacon Medical
Extra Strength CBD|T Cream, an innovative, premium cannabis topical cream for Canadian medical patients. With 500 mg of cannabidiol (CBD) per 50-gram unit, in a proprietary formulation that includes carefully curated ingredients with anti-oxidant, anti-inflammatory, and analgesic properties, together with skin penetration enhancers, Beacon Medical Extra Strength CBD|T Cream is designed using entourage principles to achieve synergies of bioactive ingredients and provide optimal symptom relief for medical conditions.
Delta 9 Cannabis partner receives five new retail cannabis store licences
The company said its strategic partner Oceanic Relief has received the licenses from The Newfoundland and Labrador Liquor Corporation Delta 9 owns a 5% stake in Oceanic’s production facility operations, existing retail store, and retail store expansion plans
Delta 9 Cannabis Inc (TSE:DN) (OTCQX:DLTNF) said its strategic partner Oceanic Relief Inc has been granted five new cannabis retail store licenses in the province of Newfoundland and Labrador from The Newfoundland and Labrador Liquor Corporation (NLC).
Oceanic has a Strategic Cooperation Agreement (SCA) with Delta 9 that provides a variety of services relating to cannabis production, the development of standard operating procedures and sanitation programs, and marketing services to develop the Oceanic brand and other services supporting the acquisition of its Health Canada license.